GlobeNewswire by notified

Global LNG market could split if an EU carbon tax is imposed on imports

Share

NEWS RELEASE

Global LNG market could split if an EU carbon tax is imposed on imports

Wood Mackenzie report says EU levies could create European price premium and transform LNG trade

21 March 2024 – The global liquefied natural gas (LNG) market could be transformed and potentially bifurcate if the European Union (EU) extends its carbon taxes to include LNG imports, according to the Wood Mackenzie’s latest Horizons report.

The EU has extended its Emission Trading Scheme (ETS) to shipping, meaning that LNG cargoes into Europe will be subject to a carbon tax from 2024. The report, titled Call of duties: How emission taxes on imports could transform the global LNG market’ concludes that if the trading bloc goes further and tightens it methane regulation or includes LNG in its Carbon Border Adjustment Mechanism (CBAM) – effectively placing an import duty on LNG at prevailing ETS carbon prices – then Wood Mackenzie predicts that the global LNG market would split.

“If the EU decides to apply these levies, then this will push European gas prices up but also bifurcate the global LNG market, creating a two-tier LNG market,” says Massimo Di Odoardo, Vice President of Gas & LNG Research at Wood Mackenzie. “If taxes were limited to the EU, or even extended to Japan and South Korea, trade flows would likely be optimised elsewhere to mitigate the impact.”

LNG emissions under the microscope
The report states that the environmental credentials of LNG are under increasing scrutiny. Despite emitting about half the carbon dioxide (CO2) of coal when combusted, the LNG value chain remains highly carbon intensive and plagued by methane losses.

However, it adds that while LNG players are actively working to reduce the greenhouse gas (GHG) footprint of their projects, the reluctance from buyers to pay a premium for lower-emission LNG has so far curbed sellers’ appetite to commit to major investment to reduce carbon intensity.

US LNG one of worst performers
The report adds that not all LNG projects are equal. Measured in kilograms of carbon dioxide equivalent (kg CO2e), methane accounts for 5% to 15% of overall carbon intensity in LNG projects outside the US. But for LNG projects in the US, methane can account for as much as 25% to 40%. This largely due to higher levels of methane losses caused by extensive use of pneumatic devices and compressors associated with shale gas production.

With a range of 800 to 1400 kilograms CO2 equivalent per tonne (CO2e/t) of LNG, the US has some of the world’s highest-emitting projects, with upstream reservoir type and pipeline distance to LNG plants adding to their high methane intensity,” Di Odoardo says.

He adds that’s projects with the lowest carbon emissions will gain from an import tax on emissions and targeting premium markets will boost trading profitability. However, proximity to premium markets will be key, with Qatar and Mozambique requiring high carbon prices to be lured away from proximate markets in emerging Asia, which are unlikely to introduce an import tax on emissions.

GHG emissions intensity (kg/CO₂ equivalent) by region (wellhead to LNG loading point)

To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

Source: Wood Mackenzie LNG Carbon Emissions Tool

High carbon taxes needed to decarbonise LNG
The report‘s analysis concludes that a tax on methane emissions of US$2800 per tonne (t/CH4), equivalent to US$100/t CO2e, will be effective in achieving its goal. Methane reduction remains the low-hanging fruit in emissions, with progress being made in different countries, supported by tightening domestic methane regulations.

Di Odoardo adds, “A methane import tax will help provide additional economic incentives while limiting LNG price upside. In this scenario, exporting countries will also be encouraged to introduce domestic levies and retain taxed revenues.”

However, Wood Mackenzie concludes that when it comes to overall carbon emissions, taxes imposed only in Europe will not achieve the required goal of large-scale decarbonisation of LNG projects globally and a bifurcate LNG market would be instead the most likely outcome.

“If there is to be any material impact, a carbon price closer to US$200/t CO2e will be required for LNG imports,” says Di Odoardo. “Additionally, this would have to be introduced on a global level for it to be truly effective in reducing carbon intensity and that is unlikely to happen. For now, all eyes will be on Europe to see what it does next.”

ENDS

Editor’s notes

About Horizons: The global LNG sector is complex and the market has had few regulations in terms of its greenhouse gas emissions. Wood Mackenzie’s Horizons report takes a deep dive into some of the potential scenarios if the EU decides to introduce carbon taxes on LNG imports and what these taxes mean for the world’s leading suppliers.

LNG Carbon Emissions Tool
For more information about Wood Mackenzie’s LNG Carbon Emissions Tool please click here.

For further information please contact Wood Mackenzie’s media relations team:

Kevin Baxter
+44 330 124 9400
Kevin.Baxter@woodmac.com

Mark Thomton
+1 630 881 6885
Mark.thomton@woodmac.com

Hla Myat Mon
+65 8533 8860
Hla.MyatMon@woodmac.com

The Big Partnership (UK PR agency)
woodmac@bigpartnership.co.uk

About Wood Mackenzie

Wood Mackenzie is the global insight business for renewables, energy and natural resources. Driven by data. Powered by people. In the middle of an energy revolution, businesses and governments need reliable and actionable insight to lead the transition to a sustainable future. That’s why we cover the entire supply chain with unparalleled breadth and depth, backed by over 50 years’ experience in natural resources. Today, our team of over 2,000 experts operate across 30 global locations, inspiring customers’ decisions through real-time analytics, consultancy, events and thought leadership. Together, we deliver the insight they need to separate risk from opportunity and make bold decisions when it matters most. For more information, visit woodmac.com.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders17.4.2024 02:00:00 CEST | Press release

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders MILLICOM INTERNATIONAL CELLULAR S.A. Registered Address: 2, Rue du Fort Bourbon L-1249 Luxembourg, Grand Duchy of Luxembourg – R.C.S. Luxembourg: B 40.630 – I. NOTICE The annual general meeting (“AGM”) and subsequent extraordinary general meeting (“EGM”) of the shareholders of MILLICOM INTERNATIONAL CELLULAR S.A. (“Millicom” or the “Company”) is hereby convened to be held at Hotel Le Royal, 12 Bd Royal, 2449 Luxembourg on Thursday, May 23, 2024, at 11:00 a.m. Central European Time ("CET"). To attend the AGM and EGM or vote by proxy, please follow the instructions in section IV: “Right to participate at the AGM and the EGM”. The AGM and EGM will consider and vote on the agenda points listed below. Please refer to section IX: “Notes to the Agenda Points of the AGM and EGM” to find detailed information about these proposals. II. AGENDA AGM To elect the chair of the AGM and to empower the chair of

Millicom’s Nomination Committee’s proposal for Board of Directors17.4.2024 02:00:00 CEST | Press release

Millicom’s Nomination Committee’s proposal for Board of Directors Luxembourg, April 17, 2024 – In advance of the Annual General Meeting of shareholders (“AGM”) of Millicom International Cellular S.A. (“Millicom”), to be held on May 23, 2024, Millicom’s Nomination Committee proposes: The election of Maxime Lombardini and Justine Dimovic as new Directors of the Board; The re-election of María Teresa Arnal Machado, Bruce Churchill, Aude Durand, Tomas Eliasson, Mauricio Ramos, Thomas Reynaud, and Blanca Treviño de Vega as Directors of the Board; and the election of Mauricio Ramos as Chair of the Board. Pernille Erenbjerg and Michael Golan have decided not to seek re-election. Maxime Lombardini will bring his extensive experience and track record in leading businesses in the telecommunications industry, as well as the strong knowledge of Millicom that he has gained while serving as President and Chief Operating Officer since September 2023. Justine Dimovic will bring a wealth of capital all

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)16.4.2024 23:30:00 CEST | Press release

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production of Stelara REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Unde

Atico Reports Consolidated Financial Results for 202316.4.2024 22:30:29 CEST | Press release

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico’s El Roble mine totaled 13.2 million pounds (“lbs”) of copper and 10,149 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.04 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "we had a challenging year overall, with the first half of the year facing lower than expected head grades and lower throughput due to mechanical and operational issues, coupled with a significant appreciation in the Colombian Peso throughout the year which materially increased our costs. Despite these challenges the team did a great job getting El Roble mine back on track in the

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release

Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c

HiddenA line styled icon from Orion Icon Library.Eye